TCGA-C8-A1HF-01A-11R-A137-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 11
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.620
- ALLOGRAFT_REJECTION+0.550
- MYC_TARGETS_V1+0.520
- G2M_CHECKPOINT+0.490
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.480
- OXIDATIVE_PHOSPHORYLATION+0.380
- MTORC1_SIGNALING+0.330
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.400
- TGF_BETA_SIGNALING-0.340
- APICAL_SURFACE-0.260
- WNT_BETA_CATENIN_SIGNALING-0.260
- APICAL_JUNCTION-0.210
- HEME_METABOLISM-0.200
- UV_RESPONSE_DN-0.200
- HEDGEHOG_SIGNALING-0.190
- MYOGENESIS-0.180
- NOTCH_SIGNALING-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A08P-01A-11R-A00Z-07 | — | C | 0.864 |
| 2 | TCGA-H7-8501-01A-11R-2403-07 | — | — | 0.843 |
| 3 | TCGA-XF-A9T5-01A-11R-A42T-07 | — | — | 0.839 |
| 4 | TCGA-C8-A278-01A-11R-A169-07 | — | C | 0.838 |
| 5 | F2EB65DD-59F7-4C1F-8D92-0DCF439FF41A | — | — | 0.837 |
| 6 | SRR1313135 | — | C | 0.830 |
| 7 | TCGA-C8-A12K-01A-21R-A115-07 | — | E | 0.828 |
| 8 | X29cb9797.16bb.49a5.bb14.fd9e9d48bbb4 | — | cohortA1 | 0.826 |
| 9 | SRR1313168 | — | E | 0.825 |
| 10 | BSR_02_0048_A10_S104 | — | C | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.620 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.380 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.270 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |